Summary
31.31 -0.20(-0.63%)05/17/2024
Pacira Pharmaceuticals Inc (PCRX)
Pacira Pharmaceuticals Inc (PCRX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.08 | 1.03 | -7.02 | -7.05 | -12.48 | -37.29 | -42.75 | 277.49 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 26.50 | |
| Open | 26.75 | |
| High | 27.05 | |
| Low | 26.43 | |
| Volume | 634,335 | |
| Change | -0.02 | |
| Change % | -0.08 | |
| Avg Volume (20 Days) | 354,716 | |
| Volume/Avg Volume (20 Days) Ratio | 1.79 | |
| 52 Week Range | 25.33 - 43.67 | |
| Price vs 52 Week High | -39.32% | |
| Price vs 52 Week Low | 4.62% | |
| Range | -0.93 | |
| Gap Up/Down | -1.11 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,431 | |
| EBIDTA | 167,820,000 | |
| PE Ratio | 19.4834 | |
| PEG Ratio | -3.8300 | |
| WallStreet Target Price | 46.00 | |
| Book Value | 19.1790 | |
| Earnings Per Share | 1.5100 | |
| EPS Estimate Current Quarter | 0.6200 | |
| EPS Estimate Next Quarter | 0.6900 | |
| EPS Estimate Current Year | 2.7700 | |
| EPS Estimate Next Year | 3.5600 | |
| Diluted EPS (TTM) | 1.5100 | |
| Revenues | ||
| Profit Marging | 0.1034 | |
| Operating Marging (TTM) | 0.0905 | |
| Return on asset (TTM) | 0.0376 | |
| Return on equity (TTM) | 0.0849 | |
| Revenue TTM | 681,753,984 | |
| Revenue per share TTM | 14.7060 | |
| Quarterly Revenue Growth (YOY) | 0.0420 | |
| Quarterly Earnings Growth (YOY) | 0.2910 | |
| Gross Profit (TTM) | 393,231,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 19.4834 | |
| Forward PE | 9.7656 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.4349 | |
| Revenue Enterprise Value | 2.3053 | |
| EBITDA Enterprise Value | 10.0657 | |
| Shares | ||
| Shares Outstanding | 46,546,100 | |
| Shares Float | 46,049,501 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.11 | |
| Insider (%) | 1.26 | |
| Institutions (%) | 106.94 | |
05/10 07:00 EST - globenewswire.com
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on May 14, 2024, subject to customary closing conditions.
Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
TAMPA, Fla., May 10, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced the pricing of $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on May 14, 2024, subject to customary closing conditions.
05/08 16:05 EST - globenewswire.com
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
TAMPA, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that it intends to offer, subject to market and other conditions, $250.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Pacira also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
05/08 12:36 EST - zacks.com
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
05/07 21:14 EST - seekingalpha.com
Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charles Reinhart - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Christian Pedetti - Senior Manager, Investor Relations Conference Call Participants Gregory Renza - RBC Capital Markets David Amsellem - Piper Sandler Gary Nachman - Raymond James Balaji Prasad - Barclays Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.
Pacira BioSciences, Inc. (PCRX) Q1 2024 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2024 Earnings Conference Call May 7, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Charles Reinhart - Chief Financial Officer Jonathan Slonin - Chief Medical Officer Christian Pedetti - Senior Manager, Investor Relations Conference Call Participants Gregory Renza - RBC Capital Markets David Amsellem - Piper Sandler Gary Nachman - Raymond James Balaji Prasad - Barclays Operator Thank you for standing by. My name is Hermione and I will be your conference operator today.
05/07 18:31 EST - zacks.com
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q1 Earnings
While the top- and bottom-line numbers for Pacira (PCRX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
05/07 16:00 EST - globenewswire.com
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024.
Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of 2024.
05/07 08:00 EST - globenewswire.com
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
04/30 08:00 EST - globenewswire.com
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
04/02 08:00 EST - globenewswire.com
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
03/14 09:26 EST - zacks.com
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag
Pacira (PCRX) receives the FDA's RMAT designation for its gene-therapy product candidate, PCRX-201, which is currently being developed in an early-stage study to treat osteoarthritis of the knee.
03/13 07:00 EST - globenewswire.com
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study --
03/06 08:00 EST - globenewswire.com
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
TAMPA, Fla., March 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays 26th Annual Global Healthcare Conference at 1:35 PM ET on Wednesday, March 13, 2024 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
03/01 07:06 EST - zacks.com
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues
Pacira (PCRX) reports fourth-quarter 2023 results, wherein earnings match and revenues beat estimates, driven by strong Exparel sales.
02/29 11:01 EST - zacks.com
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings
The headline numbers for Pacira (PCRX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
02/29 10:16 EST - zacks.com
Pacira (PCRX) Matches Q4 Earnings Estimates
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.80 per share a year ago.
Pacira (PCRX) Matches Q4 Earnings Estimates
Pacira (PCRX) came out with quarterly earnings of $0.89 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.80 per share a year ago.
02/29 08:00 EST - globenewswire.com
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m. ET — TAMPA, Fla.
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
— Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m. ET — TAMPA, Fla.
02/26 10:20 EST - zacks.com
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Evaluate the expected performance of Pacira (PCRX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
02/22 08:00 EST - globenewswire.com
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
TAMPA, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2023 financial results before the open of the U.S. markets on Thursday February 29, 2024. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
02/20 11:06 EST - zacks.com
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/15 08:36 EST - globenewswire.com
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator –